DCGI
- Technology
Department of Biotechnology Mission COVID Suraksha Supported Biological E Limited Novel COVID-19 vaccine candidate – CORBEVAX receives DCGI approval for Emergency Use Authorization
India’s first indigenously developed Receptor Binding Domain (RBD) protein sub-unit vaccine for COVID-19, CORBEVAXTM, developed by Biological E Limited, has…
Read More » - India
Centre issues SOPs for vaccination of persons undertaking international travel for educational purposes, or employment opportunities, or as part of India’s contingent for Tokyo Olympic games
Government of India has been supporting the efforts of States and UTs for an effective Vaccination drive under the ‘Whole…
Read More » - India
India crosses 20 Crore Cumulative COVID-19 Vaccination Coverage
India achieved a significant milestone in its ongoing COVID-19 vaccination drive today. On 130th day of the drive, the cumulative COVID…
Read More » - India
DRDO develops COVID-19 antibody detection kit
Defence Institute of Physiology and Allied Sciences (DIPAS), a laboratory of Defence Research and Development Organisation (DRDO), has developed an…
Read More » - India
DCGI approves anti-COVID drug developed by DRDO for emergency use
An anti-COVID-19 therapeutic application of the drug 2-deoxy-D-glucose (2-DG) has been developed by Institute of Nuclear Medicine and Allied Sciences…
Read More » - India
Health Ministry issues FAQs on better Clinical Management of COVID patients in ICUs
India continues to report one of the lowest COVID Case Fatality Rates (CFR) when compared to several other countries. While…
Read More » - India
DCGI approves Phase II+III trials of Oxford University vaccine by Serum Institute, Pune
The Drugs Controller General of India (DCGI) has given approval to Serum Institute of India, Pune to conduct Phase II+III…
Read More » - India
Market approval for Pneumococcal Polysaccharide Conjugate Vaccine given by DCGI
Drug Controller General of India (DCGI) has given approval to the first fully indigenously developed Pneumococcal Polysaccharide Conjugate Vaccine. This…
Read More » - India
DCGI gives Nod for Restricted Emergency Use to Itolizumab for moderate to severe COVID-19 patients
Itolizumab (rDNA origin), a monoclonal antibody which was already approved for severe chronic plaque psoriasis, has now been granted Restricted…
Read More »